XELOX及FOLFOX方案治疗晚期胃癌随机对照探究.docVIP

XELOX及FOLFOX方案治疗晚期胃癌随机对照探究[摘要] 目的 比较XELOX方案和FOLFOX方案对晚期胃癌的临床疗效和毒副反应。方法 110例晚期胃癌患者随机分为XELOX组和FOLFOX组。所有病例治疗三周期以上,按WHO标准评价并比较客观疗效和毒副反应。结果 XELOX组总有效率53.6%,TTP 6.0个月;FOLFOX组总有效率48.1%,TTP 5.8个月;两组总有效率差异无统计学意义。XELOX组手足综合征的发生率明显高于FOLFOX组(P0.05)。结论 XELOX方案和FOLFOX方案治疗晚期胃癌疗效相当,且毒副反应小,耐受性好。 [关键词] 晚期胃癌; 奥沙利铂; 卡培他滨; 5-氟脲嘧啶 [中图分类号] R735.2 [文献标识码] A [文章编号] 1673-9701(2010)05-121-02 A Randomized Clinical Study of XELOX Compared with FOLFOX in the Treatment of Advanced Gastric Cancer ZHANG Chunxia LIU Lihua Affiliated Hospital of Institute of Aviation Medicine,Beijing 100089,China [Abstract] ObjectiveTo evaluate the efficacy and toxicity of XELOX versus FOLFOX in the treatment of advanced gastric cancer. Methods110 cases with advanced gastric cancer were enrolled into this study. 56 patients and 54 patients were randomly divided into XELOX group and FOLFOX group respectively. All patients received three cycles of chemotherapy at least. The efficacy and toxicity were evaluated according to WHO standard. ResultsThe overall effective rate and time to disease progression(TTP) in XELOX group were 53.6% and 6.0 months,and in FOLFOX group were 48.1%and 5.8 months respectively. It was no significant difference between two groups. The incidence of hand-foot syndrome of XELOX was obviously higher than that of FOLFOX(P0.05). ConclusionBoth of the two regimens were effective and well tolerated in treatment of advanced gastric cancer with slight side efects. But XELOX regimen may be more comfortable to the old patients. [Key words]Advanced gastric cancer; Oxaliplatin; Capecitabine; 5-flurouracil 胃癌是我国常见的恶性肿瘤,至少80%以上的胃癌患者就诊时已为晚期[1],手术切除已不可能。对于转移性胃癌或无法用手术切除的胃癌,化疗是治疗的重要手段,但尚无统一的标准方案[2]。奥沙利铂是胃癌化疗中的热点药物,具有较小毒副反应和较好疗效等优点[3]。本院采用XELOX方案或FOLFOX方案治疗进展期胃癌,现报道如下。 1 材料与方法 1.1 研究对象 2004年4月～2009年2月我院收治的110例均经病理学证实的进展期胃癌患者,其中高分化腺癌8例,中分化腺癌18例,低分化腺癌22例,印戒细胞癌4例,黏液性腺癌3例。发病年龄均在38～75岁;男78例,女32例。随机分为两组,XELOX组56例患者,FOLFOX组54例。两组患者的一般特征具有可比性(P0.05)。 1.2 治疗方法 XELOX组奥沙利铂(L-OHP)(海南斯达制